کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2598699 | 1133148 | 2015 | 9 صفحه PDF | دانلود رایگان |
• Drug-induced liver injury (DILI) is a major safety concern in drug development.
• The utility of HepaRG cells as a model for DILI risk assessment was investigated.
• HepaRG cells exhibited a 67% sensitivity and 73% specificity at 100-fold Cmax.
• HepaRG cells distinguished relatively safe drugs from their high-risk analogs.
• HepaRG cells may be of use for DILI risk assessment.
The utility of HepaRG cells as an in vitro cell-based assay system for assessing drug-induced liver injury (DILI) risk was investigated. Seventeen DILI-positive and 15 DILI-negative drugs were selected for the assay. HepaRG cells were treated with each drug for 24 h at concentrations that were 1.6-, 6.3-, 25-, and 100-fold the therapeutic maximum plasma concentration (Cmax). After treatment, the cell viability, glutathione content, caspase 3/7 activity, lipid accumulation, leakage of lactate dehydrogenase, and albumin secretion were measured. The sensitivity and specificity were calculated to assess the ability of the assay to predict DILI. Our multiparametric assay using HepaRG cells exhibited a 67% sensitivity and 73% specificity at a 100-fold concentration of Cmax and a 41% sensitivity and 87% specificity at a 25-fold concentration of Cmax. When a 25-fold Cmax cut-off was applied, approximately 70% of drugs exhibiting positive responses were classified into the high DILI risk category. HepaRG cells distinguished relatively safe drugs from their high-risk analogs. Our study indicates that HepaRG cells may be of use to (1) prioritize drug analogs, (2) analyze the mechanism of DILI, and (3) assess the risk for DILI in the early drug discovery stage.
Journal: Toxicology Letters - Volume 236, Issue 1, 2 July 2015, Pages 16–24